

Reference number
2054-A

SPECIALTY GUIDELINE MANAGEMENT

FABRAZYME (agalsidase beta)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Fabrazyme is indicated for use in patients with Fabry disease. Fabrazyme reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types.

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Fabry disease

Indefinite authorization may be granted for treatment of Fabry disease when the diagnosis of Fabry disease was confirmed by enzyme assay demonstrating a deficiency of alpha-galactosidase enzyme activity or by genetic testing, or the member is a symptomatic obligate carrier.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

1. Fabrazyme [package insert]. Cambridge, MA: Genzyme Corporation; May 2010.
2. Desnick RJ, Brady RO. Fabry disease in childhood. *J Pediatr.* 2004;144(5 Suppl):S20-S26.
3. Biegstraaten M, Arngrimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet J Rare Dis.* 2015; 1036.
4. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for for diagnosis, and enzyme replacement therapy. *Ann Intern Med.* 2003; 138(4):338.
5. Sirrs, S, Bichet DG, Iwanochko RM, et al. Canadian Fabry disease treatment guidelines 2016.